|
Centers for Advanced Research
|
Emory University School of Medicine
Atlanta, GA |
Robert Wood Johnson Medical School
New Brunswick, NJ |
Boston University School of Medicine
Boston, MA |
|
University of Virginia Medical Center
Charlottesville, VA |
Washington University Medical Center
St. Louis, MO |
UCLA School of Medicine
Los Angeles, CA |
|
University of Pittsburgh
Pittsburgh, PA |
University of Alabama
Birmingham, AL |
The University of Chicago
Chicago, IL |
Cotzias Fellowships
|
Bradley Miller, MD, Ph.D. |
University of Virginia,
Charlottesville, VA |
Distribution and Metabolic Consequences of Mitochondrial DNA Deletions in Substantia Nigra and Cultured Cells |
|
Joseph Savitt, MD, Ph.D. |
Johns Hopkins Hospital,
Baltimore, MD |
Conditional GDNF Receptor Knockout Mice: Exploring the Role of GDNF in Dopaminergic Cell Development and Survival |
|
Talene Yacoubian, MD, Ph.D. |
The University of Alabama,
Birmingham, AL |
Role of 14-3-3 Proteins in Alpha Synuclein Induced Neurotoxicity |
CRoger Duvoisin, MD Grant
|
Andrei Alexandrescu, Ph.D. |
University of Connecticut
Storrs, CT |
Stability and Solvent Accessibility of Alpha-Synuclein Fibrils by NMR Hydrogen Exchange |
|
James L. Roberts, MD, Ph.D. |
University of Texas Health Science Center
San Antonio, TX |
Molecular and Cellular Mechanisms of Estrogen Midiated Neuroprotection of Mesencephalic Dopaminergic Neurons |
|
Jeffry Stock, Ph.D. |
Princeton University
Princeton, NJ |
Protein Phosphatase 2A Methylation as a Therapeutic Target for Parkinson’s Disease |
Post-Doctoral Fellowships
|
Michelle Burack, MD, Ph.D. |
University of Rochester
Rochester, NY |
The Impact of Dopa-Induced Dyskinesia on Voluntary Motor Control in Patiens with Idiopathic Parkinson Disease |
|
Joanne Clark, Ph.D. |
Beth Israel Deaconess Medical Center
Boston, MA |
Activation of PGC1a by P38MAPK; Potential Interference by A-synuclein |
|
Clement Gautier, Ph.D. |
Brigham and Women Hospital
Boston, MA |
Investigation of Mitochondrial Functions in PINK 1 Knock Out Mice |
|
Melissa Geddie, Ph.D. |
Whitehead Institute for Biomedical Research, Cambridge, MA
|
Metal Ion Transport in Parkinson’s Disease |
|
Keiichi Inoue, Ph.D. |
Columbia University
New York, NY |
Novel Animal Models of PD |
|
Shilpa Iyer, Ph.D. |
University of Virginia
Charlottesville, VA |
In Vitro Characterization of Mechanisms of Mitochondrial DNA Homoplasmy |
|
Nikolaus McFarland, MD, Ph.D. |
Massachusetts General Hospital
Boston, MA |
Alpha-Synuclein Phosphorylation and Toxicity in a Rat Model of Parkinson’s |
|
Julie Tetzlaff, Ph.D. |
Massachusetts General Hospital
Boston, MA |
Therapeutic Reduction in Oligomeric Alpha-Synuclein Species |
|
Shaji Theodore, Ph.D. |
The University of Alabama
Birmingham, AL |
A Novel Mode of Microglial Activation in a Mouse Model of Parkinson’s Disease |
|
Harrison Walker, MD |
The University of Alabama
Birmingham, AL |
Clinical and Electrophysiological Investigation of Bilateral Effects of Unilateral Subthalamic Nucleus Deep Brain Stimulation |
|
Allison Wright Willis, MD |
Washington University
St. Louis, MO |
Environment Heavy Metal Exposure and the Risk of PD: A Community Health Study Using Geographical Information Systems |
Research Grants
|
Asa Abeliovich, MD, Ph.D. |
Columbia University
New York, NY |
Novel Therapeutics for PD |
|
Sarah Berman, MD, Ph.D. |
University of Pittsburgh
Pittsburgh, PA |
Exploration of Mitochondrial Dynamics in Models of Parkinson’s Disease |
|
Guy Caldwell, Ph.D. |
The University of Alabama
Tuscaloosa, AL |
Identification and Functional Validation of Neuroprotective Genes Associated with Parkinson’s Disease |
|
Sreeganga Chandra, Ph.D. |
Yale University
New Haven, CT |
Delineating the Physiological Functions of Synucleins |
|
Sylvain Dore, Ph.D. |
Johns Hopkins University School of Med.
Baltimore, MD |
PGE2 EP1 Receptor Role in Parkinsonism |
|
Ray Dorsey, MD |
University of Rochester
Rochester, NY |
A Guide to Improving the Impact of Parkinson Disease Research |
|
Andrea Giuffrida, Ph.D. |
University of Texas Health Science Center
San Antonio, TX |
Neuroprotective Role of Cannabinoids in Parkinson’s Disease |
|
Matthew Goldberg, Ph.D. |
UT Southwestern Medical Center
Dallas, TX |
Parkin, DJ-1 and Antioxidant-deficient Mouse Models of PD |
|
Ming Guo, MD, Ph.D. |
Brain Research Institute at UCLA
Los Angeles, CA |
Characterization of the Function of a PINK 1 Binding Protein |
|
Syed Iman, Ph.D. |
University of Texas Health Science Center
San Antonio, TX |
Evaluation of Stress-induced Tyrosine Kinase, c-Abl, as a Novel Therapeutic Target for Parkinson’s Disease |
|
Steven Johnson, MD, Ph.D. |
Portland VA Research Foundation
Portland, OR |
Redox Regulation of NMDA Currents in Midbrain Dopamine Neurons |
|
Andreas Kottmann, Ph.D. |
Columbia University
New York, NY |
On the Function of the Secreted Cell-Signaling Glycoprotein Sonic Hedgehog (Shh) Expressed by Mesencephalic Dopaminergic Neurons in the Postnatal Brain |
|
Lawrence Kromer, Ph.D. |
Georgetown University
Washington, DC |
Role of Ephrins and Eph Receptors in Regulating Striatal Reinnervation by Dopaminergic Grafts |
|
Matthew LaVoie, Ph.D. |
Brigham and Women’s Hospital
Boston, MA |
Dissecting the anti-Apoptotic Function of Parkin and the Impact of PD-Linked Parkin Mutations |
|
Zhicheng Lin, Ph.D. |
The McLean Hospital Corporation
Belmont, MA |
Genetic Variation in Human Alpha-Synuclein Expression |
|
Changwei Liu, Ph.D. |
University of Colorado at Denver
Aurora, CO |
Studying of the Role of the CHIP/Hsp70 E3 Ligase in Mediating the Ubiquitination of Serine 129 Phosphorylated Alpha-Synuclein |
|
Nigel Maidment, Ph.D. |
UCLA
Los Angeles, CA |
Is VMAT Over-Expression Neuroprotective in Mammalian Alpha-Synuclein Models of PD |
|
Anthony Nicholas, MD, Ph.D. |
The University of Alabama
Birmingham, AL |
Post-Translational Modifications of Histones in Levodopa-Induced Dyskinesia |
|
Janis O’Donnell, Ph.D. |
University of Alabama
Tuscaloosa, AL |
In Vivo Analysis of the Role of 14-3-3 Zeta and Over-expression in Neurodegeneration in a Drosophilia PD Model |
|
Owen Ross, Ph.D. |
Mayo Clinic Jacksonville
Jacksonville, FL |
Dysregulation of A-Synuclein Gene Expression in Parkinson’s Disease |
|
Jay Schneider, Ph.D. |
Thomas Jefferson University
Philadelphia, PA |
Functional Significance of ALDH1 in Ventral Mesencephalic Dopamine Neurons |
|
Lidia Serova, Ph.D. |
New York Medical College
Valhalla, NY |
Mechanism of Interaction Between Nicotine and Estradiol as Related to Tetrahydrobiopterin in Animal Model of Parkinson’s Disease |
|
Paul Shaw, Ph.D. |
Washington University
St. Louis, MO |
Evaluating Protective Effects of Curcum in Synuclein Pathology |
|
Wanli Smith, MD, Ph.D. |
Johns Hopkins University School of Med.
Baltimore, MD |
Cytoplasmic LRRK2 Inclusion and Ubiquitination |
|
Stephanie White, Ph.D. |
University of California
Los Angeles, CA |
Birdsong as a Model System for Parkinson’s Disease |
|
Stephan Witt, Ph.D. |
Louisiana State University Health Sci. Ctr.Shreveport, LA |
Determining Why Phosphorylation of Alpha-Synuclein at Serine 129 Causes Toxicity |
|
Baoji Xu, Ph.D. |
Georgetown University
Washington, DC |
Chronic Deprivation of TrkB Signaling Leads to Progressive and Selective Nigrostriatal Dopaminergic Degeneration |
|
Jin Xu, Ph.D. |
Caritas St. Elizabeth’s Medical Ctr.
Boston, MA |
Functional Interplay Between DJ-1 and PGC-la |
|
Cyrus Zabetian, MD, MS |
Seattle Institute for Biomedical & Clinical
Research, Seattle, WA |
Fine-mapping of a Chromosome 17q21 Region Associated with Parkinson’s Disease |
|
Fu-Ming Zhou, Ph.D. |
University of Tennessee
Memphis, TN |
An Ultra-Short Dopamine Pathway: Implications for Parkinson’s Disease |
|
Wenbo Zhou, Ph.D. |
University of Colorado Health Sci. Ctr.
Denver, CO |
Testing Drugs that Upregulate DJ-1 in Mouse Models of Parkinson’s Disease |
|